These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapy of the bronchitic syndrome (author's transl)].
    Author: Danilewicz A, Kronberger O, Vogel D.
    Journal: Wien Klin Wochenschr; 1975 May 02; 87(9):313-5. PubMed ID: 1136518.
    Abstract:
    The bronchitic syndrome necessitates chemotherapeutic management, especially in view of the secondary complications arising in this condition. Chemotherapy must be consistently adhered to, not only during acute exacerbations, but also during the relatively symptom-free intervals between exacerbations and also in those cases displaying minimal symptomatology. A useful criterion of the necessity for chemotherapy is the presence of a purulent sputum and with the appearance of this feature, specific chemotherapy should be initiated without delay (W. T. Ulmer). Appropriate investigations in 41 patients showed that Lidaprim, a combined preparation of trimethoprim and sulfametrol, can be recommended on the basis of its beneficial chemotherapeutic effect, good tolerability and simplicity of administration. Purulence of the sputum disappeared within 10 days of commencement of treatment with 2 times 2 tablets Lidaprim daliy in 38 out of the 41 patients. The clinical symptoms, including respiratory difficulties, improved simultaneously with the decrease in quantity of expectorated sputum. Lidaprim represents a useful and effective chemotherapeutic agent in the hands of both the hospital specialist and the general practitioner for treatment of the bronchitic syndrome in all its diverse forms.
    [Abstract] [Full Text] [Related] [New Search]